ArticleJournal of epidemiology and global health2023
Global Burden of Prostate Cancer and Association with Socioeconomic Status, 1990-2019: A Systematic Analysis from the Global Burden of Disease Study.
Article in Journal of epidemiology and global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy of androgen deprivation therapy (ADT) in combination with radiation therapy, compared to ADT alone in patients with high-risk prostate cancer: an updated systematic review and meta-analysis.Journal of medicine and life · 2026Pooled it
- The Radical Prostatectomy Versus Brachytherapy for the Management of Low- and Intermediate-Risk Prostate Cancer: A Meta-Analysis of Observational Studies Focusing on Oncological Outcomes.Asian Pacific journal of cancer prevention : APJCP · 2026Pooled it
- Matching-adjusted indirect comparison of talazoparib plus enzalutamide versus abiraterone acetate and docetaxel in mCRPC.Future oncology (London, England) · 2025Pooled it
- Pooled it
- The association between zinc and prostate cancer development: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Predicting disease progression and mortality in prostate cancer using real-world data-driven time-inhomogeneous Markov models.iScience · 2026Article
- Temporal trends, future projections, and burden of early-onset genitourinary cancers in Asia from 1990 to 2023: an analysis of the Global Burden of Disease Study 2023.Translational andrology and urology · 2026Article
- Fully GMP-complient radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2026Article
- Insulin-like growth factor-binding protein 5 promotes prostate cancer metastasis and osteoblastic activity by inducing chemokines and activating NF-κB signaling.Cancer cell international · 2026Article
- Complete tumor regression with exclusive Ayurvedic treatment in adenocarcinoma of prostate: a case report.Journal of medical case reports · 2026Article
- Prediction of molecular subtypes from histology: AI-driven analysis of prostate cancer morphological patterns and therapeutic implications.NPJ precision oncology · 2026Article
- Global, regional, and national burden of early-onset prostate cancer, 1990-2021: a systematic analysis for the global burden of disease study 2021.World journal of surgical oncology · 2026Article
- Advanced prostate cancer presenting as bulky loco-regional disease without distant metastasis: a case report with review of the management - What is the optimal treatment?Annals of medicine and surgery (2012) · 2026Article
- Presence of Trace Metals in the Biological Samples of Prostate Cancer Patients: A Systematic Review of Case-Control Studies.Cancers · 2026Review
- Global prostate cancer risk associated with microplastic exposure: a statistical and machine learning analysis.Frontiers in public health · 2026Article
- Diagnostic accuracy of prostate-specific antigen and prostate-specific antigen density in patients suspected of having prostate cancer in South Korea: A large, multi-institutional registry.Investigative and clinical urology · 2026Article
- Central and peripheral areal BMD, bone microarchitecture, and strength after initiation of androgen deprivation therapy in men with prostate cancer: a two-year follow-up study.Frontiers in endocrinology · 2026Observational
- TRPV1 Downregulation Impairs Prostate Cancer Growth: Functional and Translational Insights from Cellular andInternational journal of biological sciences · 2026Article
- Evaluating a Behavioural Theory-Based Board Game (S-S-LIBOG) Against Traditional Health Talk (HT) in Prostate Cancer Education: Findings from a Quasi-Experimental Study, Plus Introducing 17 Other S-S-LIBOGs.Healthcare (Basel, Switzerland) · 2025Article
- Prostate Cancer Mortality Trend in Montenegro 1990-2018.Iranian journal of public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
importanceBoth the morbidity and mortality of prostate cancer are increasing worldwide. Updated evaluations of prostate cancer burden and its global, regional and national patterns are essential for formulating effective preventive strategies.
objectiveTo investigate prostate cancer incidence, mortality, and disability-adjusted life years (DALYs) between 1990 and 2019 to facilitate preventive measures and control planning.
methodsAnnual incident cases, deaths, DALYs, age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), and age-standardized DALYs rates (ASDRs) of prostate cancer between 1990 and 2019 were derived from the Global Burden of Diseases study 2019. Percentage changes in incident cases, deaths and DALYs and estimated annual percentage changes (EAPCs) in ASIRs, ASMRs and ASDRs were calculated to quantify temporal trends. Correlations between EAPCs and socio-demographic index (SDI) and universal health coverage index (UHCI) were evaluated by Pearson correlation analyses.
resultsGlobally, the number of incident cases, deaths, and DALYs of prostate cancer increased by 116.11%, 108.94%, and 98.25% from 1990 to 2019, respectively. The ASIR increased by an average of 0.26% (95% CI: 0.14%, 0.37%) per year between 1990 and 2019, while the ASMR and ASDR decreased by an average of - 0.75% (95% CI: - 0.84%, - 0.67%) and - 0.71% (95% CI: - 0.78%, - 0.63%) per year in this period, respectively. Epidemic trends in the burdens of prostate cancer were not uniform throughout different groups of SDI or geography. The burdens of prostate cancer varied across SDI regions, with an increasing trend in ASIR, ASMR, and ASDR in low and low-middle SDI regions between 1990 and 2019. A significant positive correlation between the EAPC in ASIR and UHCI was observed in countries with a UHCI < 70 (ρ = 0.37, p < 0.001).
interpretationProstate cancer remains a major global health burden due to the increase in incident cases, deaths, and DALYs in the past three decades. These increases are likely to continue as the population ages, which indicates a potential talent gap in the trained healthcare workforce. The diversity of prostate cancer development models implies the importance of specific local strategies tailored for each country's risk factor profile. Prevention, early detection and more effective treatment strategies for prostate cancer are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.